Source:http://linkedlifedata.com/resource/pubmed/id/12210406
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2002-9-4
|
| pubmed:abstractText |
This study aimed to investigate the factors associated with viral breakthrough among liver transplant recipients who receive lamivudine monoprophylaxis. Consecutive patients receiving liver transplantation for HBV-related liver disease from June 1999 to October 2000 were studied. All patients received lamivudine 100 mg daily pre- and post-transplant. Serum samples were collected before lamivudine treatment, before liver transplantation, and then every 3-6 months after liver transplantation. Lamivudine-resistant mutations at the YMDD motif of HBV P gene were detected by direct sequencing and HBV DNA was quantified by real-time polymerase chain reaction (PCR). Ten patients, 7 males and 3 females, aged 50.5 +/- 7.9 years, were studied. Three patients had fulminant hepatitis and 7 patients had end-stage cirrhosis before liver transplantation. Lamivudine was started at 4.5 (range 0-40) weeks before liver transplantation. The median post-transplant follow-up was 16 (range 12-23) months. Four patients developed YMDD mutations 10.5 (0-16) months after transplantation with relapse of viraemia (median 1,294, range 51-3,135 MEq/ml). All patients who developed YMDD mutants had end-stage liver cirrhosis, and HBV DNA were detectable on the day of liver transplantation (median 0.62, range 0.086-1.63 MEq/ml). On the contrary, all 3 patients transplanted for fulminant hepatitis did not have YMDD mutation. Among the 3 end-stage cirrhotic patients who had negative HBV DNA before liver transplantation, none developed YMDD mutation. In conclusion, patients transplanted for fulminant hepatitis B and cirrhotic patients in whom HBV DNA could be rendered PCR negative before liver transplantation are unlikely to develop YMDD mutation on lamivudine monoprophylaxis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0146-6615
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2002 Wiley-Liss, Inc.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
68
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
182-7
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:12210406-Adult,
pubmed-meshheading:12210406-Amino Acid Motifs,
pubmed-meshheading:12210406-Amino Acid Sequence,
pubmed-meshheading:12210406-Antiviral Agents,
pubmed-meshheading:12210406-Base Sequence,
pubmed-meshheading:12210406-DNA, Viral,
pubmed-meshheading:12210406-Drug Resistance, Viral,
pubmed-meshheading:12210406-Female,
pubmed-meshheading:12210406-Genes, Viral,
pubmed-meshheading:12210406-Hepatitis B,
pubmed-meshheading:12210406-Hepatitis B e Antigens,
pubmed-meshheading:12210406-Hepatitis B virus,
pubmed-meshheading:12210406-Humans,
pubmed-meshheading:12210406-Lamivudine,
pubmed-meshheading:12210406-Liver Cirrhosis,
pubmed-meshheading:12210406-Liver Transplantation,
pubmed-meshheading:12210406-Male,
pubmed-meshheading:12210406-Middle Aged,
pubmed-meshheading:12210406-Mutation,
pubmed-meshheading:12210406-Recurrence
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
|
| pubmed:affiliation |
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong. hlychan@hotmail.com
|
| pubmed:publicationType |
Journal Article
|